Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Robert C. Chick, Guy T. Clifton, Diane F. Hale, Timothy J. Vreeland, Annelies T. Hickerson, Phillip M. Kemp Bohan, Patrick M. McCarthy, Jennifer K. Litton, Gheath Alatrash, Rashmi K. Murthy, Na Qiao, Anne V. Philips, Jason Lukas, Jarrod P. Holmes, Elizabeth A. Mittendorf, George E. Peoples